Related Experiment Video
Updated: Jun 2, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
Published on: February 24, 2023
Primary central-nervous-system lymphoma - treatment with multiagent systemic and intrathecal chemotherapy with
1UNIV MICHIGAN,MED CTR,DEPT NEUROL,1500 E MED CTR DR,1914 TAUBMAN CTR,BOX 0316,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT SURG,NEUROSURG SECT,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109. WESTERN GEN HOSP,DEPT CLIN NEUROSCI,NEUROL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.
Abstract:
Nine patients with primary central nervous system lymphoma (PCNSL) were evaluated in a protocol of systemic and intrathecal chemotherapy and radiation therapy (RT). The median survival was 30 months; median time to recurrence was 14 months. Leukoencephalopathy developed in 7/9 patients, 6-12 months after combination therapy. 5/9 patients worsened cognitively 6-14 months after therapy; all developed leukoencephalopathy. The four patients who had an initial positive cytology or delayed CSF outflow did not worsen cognitively, although two developed leukoencephalopathy. The combination of chemotherapy and RT improves survival of patients with PCNSL; however, leukoencephalopathy and cognitive changes are frequent.
Related Concept Videos
Treatment Resistent Cancers
Cryptococcal Meningitis
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...